Clinical Trial Update: HAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE Failure [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating hepatic arterial infusion chemotherapy (HAIC) combined with camrelizumab and tyrosine kinase inhibitor (TKI) for unresectable hepatocel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Camrelizumab (camrelizumab)
• HAIC (hepatic artery infusion chemotherapy)
• TKI (tyrosine kinase inhibitor)

Snippet

Sponsor: Yue Han | Conditions: Unresectable Hepatocellular Carcinoma | Phase 2 | Status: UNKNOWN